U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy

Cure SMA Webinar on Spinraza(TM) Approval - U.S. OnlyПодробнее

Spinraza (Nusinersen) Approved by FDA for SMA Patients - Ionis Pharmaceuticals / BiogenПодробнее

U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular AtrophyПодробнее

U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular AtrophyПодробнее

Nusinersen (SpinrazaTM): The First FDA Approved Treatment for SMAПодробнее

Nusinersen: The First Approval for Spinal Muscular AtrophyПодробнее

The Development Journey of Spinraza® (nusinersen): From Advocacy to Treatment and BeyondПодробнее

FDA approves SMA drug SpinrazaПодробнее

Spinraza (nusinersen) ApprovalПодробнее

FDA approves SMA drugПодробнее

SPINRAZA® (nusinersen) Mechanism of Action in Spinal Muscular AtrophyПодробнее

Spinal Muscular Atrophy 2019: Approved Treatment and Upcoming Therapeutic StrategiesПодробнее

Cut and Paste: Treating Spinal Muscular Atrophy with NusinersenПодробнее

How Spinraza (nusinersen) and Evrysdi treat Spinal Muscular Atrophy (SMA) through splice-switchingПодробнее

Lancet Study on Spinal Muscular Atrophy - Nemours Children's HospitalПодробнее

Exciting News Regarding Biogen and SpinrazaПодробнее

2020 Science Writers' Boot Camp: New Treatments for Spinal Muscular Atrophy—Neurodegenetic DiseasesПодробнее

Nusinersen for Treatment of SMAПодробнее

Cure SMA's Zolgensma FDA Approval WebinarПодробнее